When a Food and Drug Administration advisory panel meets Monday to size up an Eli Lilly experimental Alzheimer’s drug, questions about safety, selection of patients for treatment, and dosing will be at the fore, documents released Thursday show.
Eli Lilly’s Alzheimer’s drug to face safety, dosing scrutiny from FDA advisers
